FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:502-511 January 31, 2008 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Burstein, H. J. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Cancer is caused by alterations in oncogenes, tumor-suppressor genes, and microRNA genes. These alterations are usually somatic events, although germ-line mutations can predispose a person to heritable or familial cancer. A single genetic change is rarely sufficient for the development of a malignant tumor. Most evidence points to a multistep process of sequential alterations in several, often many, oncogenes, tumor-suppressor genes, or microRNA genes in cancer cells.

Tumors often possess cytogenetically different clones that arise from the initial transformed cell through secondary or tertiary genetic alterations. This heterogeneity contributes to differences in clinical behavior and responses to treatment of tumors . . . [Full Text of this Article]

Evidence of Somatic Genetic Change

Functional Properties of Oncogenes

Products of Oncogenes

            Transcription Factors

            Chromatin Remodelers

            Growth Factors

            Growth Factor Receptors

            Signal Transducers

            Apoptosis Regulators

Oncogene Activation

            Chromosomal Rearrangements

            Mutations

            Gene Amplification

Oncogenes in Cancer Initiation and Progression

Oncogenes as Therapeutic Targets

MicroRNA Genes

Summary

Source Information

From the Department of Molecular Virology, Immunology, and Medical Genetics and the Human Cancer Genetics Program, Ohio State University Medical Center, Columbus.

Address reprint requests to Dr. Croce at the Human Cancer Genetics Program and Department of Molecular Virology, Immunology, and Medical Genetics, Ohio State University Medical Center, 385L Wiseman Hall, 400 W. 12th Ave., Columbus, OH 43210, or at carlo.croce@osumc.edu.

This article has been cited by other articles:

• Bao, R., Lai, C.-J., Qu, H., Wang, D., Yin, L., Zifcak, B., Atoyan, R., Wang, J., Samson, M., Forrester, J., DellaRocca, S., Xu, G.-X., Tao, X., Zhai, H.-X., Cai, X., Qian, C. (2009). CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy. Clin. Cancer Res. 15: 4046-4057 [Abstract] [Full Text]  
• Li, Z., Hassan, M. Q., Jafferji, M., Aqeilan, R. I., Garzon, R., Croce, C. M., van Wijnen, A. J., Stein, J. L., Stein, G. S., Lian, J. B. (2009). Biological Functions of miR-29b Contribute to Positive Regulation of Osteoblast Differentiation. J. Biol. Chem. 284: 15676-15684 [Abstract] [Full Text]  
• Yu, J., Ershler, M., Yu, L., Wei, M., Hackanson, B., Yokohama, A., Mitsui, T., Liu, C., Mao, H., Liu, S., Liu, Z., Trotta, R., Liu, C.-g., Liu, X., Huang, K., Visser, J., Marcucci, G., Plass, C., Belyavsky, A. V., Caligiuri, M. A. (2009). TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemia. Blood 113: 5558-5567 [Abstract] [Full Text]  
• Saidak, Z., Mentaverri, R., Brown, E. M. (2009). The Role of the Calcium-Sensing Receptor in the Development and Progression of Cancer. Endocr. Rev. 30: 178-195 [Abstract] [Full Text]  
• Barros Costa, R. L. (2009). Review Article: Targeted Therapy: Comprehensive Review. AM J HOSP PALLIAT CARE 26: 137-146 [Abstract]  
• Fiaschi-Taesch, N., Bigatel, T. A., Sicari, B., Takane, K. K., Salim, F., Velazquez-Garcia, S., Harb, G., Selk, K., Cozar-Castellano, I., Stewart, A. F. (2009). Survey of the Human Pancreatic {beta}-Cell G1/S Proteome Reveals a Potential Therapeutic Role for Cdk-6 and Cyclin D1 in Enhancing Human {beta}-Cell Replication and Function In Vivo. Diabetes 58: 882-893 [Abstract] [Full Text]  
• Li, J., Wang, L., Janne, P. A., Makrigiorgos, G. M. (2009). Coamplification at Lower Denaturation Temperature-PCR Increases Mutation-Detection Selectivity of TaqMan-Based Real-Time PCR. Clin. Chem. 55: 748-756 [Abstract] [Full Text]  
• Smallridge, R. C, Marlow, L. A, Copland, J. A (2009). Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 16: 17-44 [Abstract] [Full Text]  
• Childs, G., Fazzari, M., Kung, G., Kawachi, N., Brandwein-Gensler, M., McLemore, M., Chen, Q., Burk, R. D., Smith, R. V., Prystowsky, M. B., Belbin, T. J., Schlecht, N. F. (2009). Low-Level Expression of MicroRNAs let-7d and miR-205 Are Prognostic Markers of Head and Neck Squamous Cell Carcinoma. Am. J. Pathol. 174: 736-745 [Abstract] [Full Text]  
• Choi, J. H., Sheu, J. J.-C., Guan, B., Jinawath, N., Markowski, P., Wang, T.-L., Shih, I.-M. (2009). Functional Analysis of 11q13.5 Amplicon Identifies Rsf-1 (HBXAP) as a Gene Involved in Paclitaxel Resistance in Ovarian Cancer. Cancer Res. 69: 1407-1415 [Abstract] [Full Text]  
• Lund, E., Dumeaux, V. (2008). Systems Epidemiology in Cancer. Cancer Epidemiol. Biomarkers Prev. 17: 2954-2957 [Abstract] [Full Text]  
• Wistuba, I. I., Meyerson, M. (2008). Chromosomal Deletions and Progression of Premalignant Lesions: Less Is More. Cancer Prevention Research 1: 404-408 [Full Text]  
• Miller, T. E., Ghoshal, K., Ramaswamy, B., Roy, S., Datta, J., Shapiro, C. L., Jacob, S., Majumder, S. (2008). MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1. J. Biol. Chem. 283: 29897-29903 [Abstract] [Full Text]  
• Chitnis, M. M., Yuen, J. S.P., Protheroe, A. S., Pollak, M., Macaulay, V. M. (2008). The Type 1 Insulin-Like Growth Factor Receptor Pathway. Clin. Cancer Res. 14: 6364-6370 [Abstract] [Full Text]  
• Li, Z., Hassan, M. Q., Volinia, S., van Wijnen, A. J., Stein, J. L., Croce, C. M., Lian, J. B., Stein, G. S. (2008). A microRNA signature for a BMP2-induced osteoblast lineage commitment program. Proc. Natl. Acad. Sci. USA 105: 13906-13911 [Abstract] [Full Text]  
• Quaye, L., Gayther, S. A., Ramus, S. J., Di Cioccio, R. A., McGuire, V., Hogdall, E., Hogdall, C., Blaakr, J., Easton, D. F., Ponder, B. A.J., Jacobs, I., Kjaer, S. K., Whittemore, A. S., Pearce, C. L., Pharoah, P. D.P., Song, H. (2008). The Effects of Common Genetic Variants in Oncogenes on Ovarian Cancer Survival. Clin. Cancer Res. 14: 5833-5839 [Abstract] [Full Text]  
• Pichiorri, F., Suh, S.-S., Ladetto, M., Kuehl, M., Palumbo, T., Drandi, D., Taccioli, C., Zanesi, N., Alder, H., Hagan, J. P., Munker, R., Volinia, S., Boccadoro, M., Garzon, R., Palumbo, A., Aqeilan, R. I., Croce, C. M. (2008). MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc. Natl. Acad. Sci. USA 105: 12885-12890 [Abstract] [Full Text]  
• Gabriely, G., Wurdinger, T., Kesari, S., Esau, C. C., Burchard, J., Linsley, P. S., Krichevsky, A. M. (2008). MicroRNA 21 Promotes Glioma Invasion by Targeting Matrix Metalloproteinase Regulators. Mol. Cell. Biol. 28: 5369-5380 [Abstract] [Full Text]  
• Tam, C. S., Nussenzveig, R. M., Popat, U., Bueso-Ramos, C. E., Thomas, D. A., Cortes, J. A., Champlin, R. E., Ciurea, S. E., Manshouri, T., Pierce, S. M., Kantarjian, H. M., Verstovsek, S. (2008). The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood 112: 1628-1637 [Abstract] [Full Text]  
• Strutz, F. (2008). The great escape--myofibroblasts in fibrosis and the immune system. Nephrol Dial Transplant 23: 2477-2479 [Full Text]